Our Science

Interferon β

Interferon beta (IFN-β) is a naturally occurring protein, which orchestrates the body's antiviral responses. Viruses, including coronaviruses, have evolved mechanisms which suppress natural IFN-β production, thereby helping the virus evade the immune system.

Inhaled Interferon β

In the laboratory, IFN-β has been shown to protect cells from infection with a broad range of respiratory viruses that cause lower respiratory illness including highly pathogenic coronavirus strains, including MERS-CoV, SARS-CoV and SARS-CoV-2, the virus which causes COVID-19.

Synairgen’s primary focus is developing our investigative inhaled IFN-β candidate (SNG001) to meet the urgent need for the treatment of COVID-19 and other severe viral lung infections as potentially the first host-directed, broad-spectrum antiviral treatment delivered directly into the lungs.

Host-directed antivirals strengthen the cell’s antiviral defences, so they are better able to fight off the virus.

Not all antivirals are the same

Watch this short animation to learn the difference between host-directed antivirals and direct acting antivirals.

Programmes & Clinical Trials

Synairgen's primary focus is developing inhaled interferon beta to meet the urgent need for the treatment of COVID-19.